Abstract:Crohn's disease (CD) is an inflammatory bowel disease that causes inflammation and stricture, of any part of the mucosa and the gut wall. It forms skip lesions, sparing the areas in between the affected parts of the gastrointestinal tract. Crohn's disease could have one of three complications; fistula, intestinal obstruction due to stricture, or gastrointestinal inflammation presenting as severe diarrhoea. Stem cell therapy (SCT) is an innovative treatment that has been recently used in CD. The exact role of SCT in CD is still unclear. Stem cells modify the immunity of the patients or act as a "reset tool" for the immune system as in the case of systemically‐injected stem cells, or regenerate the affected area of necrotic and inflammatory tissue as in the case of local injection into the lesion. Stem cells are a wide variety of cells including pluripotent stem cells or differentiated stem cells. The hazards range from rejection to symptomatic manifestations as fever or increase infection. The objective of this Cochrane systematic review is to assess the effects of stem cell transplantation compared to standard of care alone or with placebo on efficacy and safety outcomes in patients with refractory CD. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trial registries (Clinicaltrials.gov, World Health Organization‐International Clinical Trials Registry Platform WHO ICTRP) from inception to 19 March 2021, without any language, publication year, or publication status restrictions. In addition, we searched references of included studies and review articles for further references. An update of the published studies was done during the writing of the review. We included only randomised controlled trials (RCTs) that assessed the effectiveness and safety of SCT in refractory CD versus standard care alone (control) or with placebo. Two review authors (SEN and SFA) independently screened the studies retrieved from the search results for inclusion, extracted data and assessed the risk of bias. Any disagreement was resolved through a consensus between the authors. We used standard methodological procedures expected by Cochrane. We conducted our search on 19 March 2021 and identified 639 records. We added two records by a manual search of the published reviews on the topic to a total of 641 records. The Covidence program removed 125 duplicates making a total of 516 reports. Two review authors (SEN and SFA) screened titles and abstracts and excluded 451 records with the remaining 65 for full‐text records screened independently by the two authors; only 18 studies were considered for inclusion. We included seven RCTs with a total of 442 participants for the meta‐analysis. The intervention group included 234 patients, and the control group included 208 patients. Nine trials are ongoing and, two abstracts are awaiting classification. All patients in the control and intervention groups received the standard therapy for CD. Only three studies used blinding methods for the control group in the form of a placebo, with one study of the three stated that the blinding method was inefficient. The patients and personnel were aware of the intervention in the rest of the four studies as they were open‐label trials. However, the effect of unblinding was balanced by the low risk of detection bias in five of the included studies. The evidence is uncertain about the effect of SCT on achieving clinical remission as compared to control/placebo (risk ratio (RR) 1.88, 95% Confidence Interval (CI) 0.80 to 4.41; 3 studies; low‐certainty evidence). The evidence is very uncertain about the effect of SCT on achieving Crohn's Disease Activity Index (CDAI) <150 at 24 weeks compared to control (RR1.02 95% CI 0.67 to 1.56; 4 studies; very‐low certainty evidence). SCT is likely to achieve fistula closure as compared to the control/placebo both in the short term (RR 1.48, 95% CI 1.12 to 1.96); low‐certainty evidence) and in the long term (RR 1.42, 95% CI 1.09 to 1.87; 4 studies; low‐certainty evidence) follow‐up. The evidence is very uncertain about the effect of SCT to cause no difference in the number of total adverse events as compared to the control/placebo (RR 0.99, 95% CI [0.88 to 1.13); 4 studies; very‐low‐certainty evidence). However, SCT is likely to increase the number of serious adverse events as compared to the control/placebo (RR 1.22, 95% CI 0.88 to 1.67; 7 studies; low‐certainty evidence). The evidence is very uncertain about the effect of SCT to decrease the withdrawal due to adverse events as compared to the control/placebo (RR 0.78, 95% CI 0.32 to 1.89; 3 studies; very‐low certainty evidence). Funding by pharmaceutical companies was found in three studies, with one including more than 50% of our studied population. SCT shows an uncertain effect on clinical remission with low certainty of evidence. SCT shows an uncert -Abstract Truncated-

Strategies and methods of medical therapy for refractory Crohn's disease

Current Strategies For The Treatment Of Ulcerative Colitis

Clinical Treatment Strategy of Crohn' s Disease

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Advances in early diagnosis and treatment of Crohn's disease

Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations

Therapeutic Choice in the Management of Crohn Disease

Biologic dual target therapy for refractory Crohn′s disease: five cases and literature review

The Efficacy and Safety of Methotrexate in Refractory Crohn’s Disease

A New Strategy for Medical Therapy of Crohn's Disease:The Top-Down Approach

Advancements in Targeted Therapies for the Management of Crohn's Disease: A Comprehensive Review

Clinical characteristics and risk factors of refractory Crohn's disease

A review of the therapeutic management of Crohn's disease

Current Status, Challenges, and Future Directions in Crohn's Disease

Research progress on acupuncture and moxibustion for treatment of Crohn's disease based on the regulation of innate immunity

The potential for medical therapies to address fistulizing Crohn's disease: a state-of-the-art review

Novel and emerging drugs for the treatment of Crohn's disease: a review of phase II and III trials

Treatment of Inflammatory Bowel Disease: A Comprehensive Review

Crohn's targeted therapy: myth or real goal?

Intestinal stricture in Crohn's disease: A 2020 update

Stem cell transplantation for induction of remission in medically refractory Crohn's disease.